A Study of LP-168 in Participants With Relapse or Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multi-center Phase 2 study of oral LP-168 in patients with
mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's
tyrosine kinase (BTK) inhibitor.